Composition, form of production and packaging
? Capsules soft gelatinous, opaque, size 4, oval, consisting of two longitudinal halves of white / light green color; the contents of the capsules are an oily liquid of brown color.
1 caps.
bark extract of African plum 50 mg
[PRING] peanut oil (150 mg).
Composition of the shell: gelatin, glycerol, titanium dioxide, copper-chlorophyllin sodium.
10 pieces. - blisters (1) - packs of cardboard.
10 pieces. - blisters (2) - packs of cardboard.
10 pieces. - blisters (3) - packs of cardboard.
30 pcs. - blisters (1) - packs of cardboard.
30 pcs. - blisters (2) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
The product description was approved by the manufacturer for the 2009 print edition.
PHARMACHOLOGIC EFFECT
A preparation of vegetable origin for the treatment of benign prostatic hyperplasia. Reduces the proliferation of prostate cells. Has anti-inflammatory and anti-edematous effect. The effect is determined by the antiproliferative effect on fibroblasts stimulated by b-FGF (the main fibroblast growth factor). Eliminates and reduces functional disorders of urination - dysuria, nocturia, pollakiuria with diseases of the prostate gland. Reduces the inflammatory reaction in the tissues of the prostate gland and promotes the intensification of its secretory activity; reduces the amount of residual tissue after surgery.
PHARMACOKINETICS
Data on the pharmacokinetics of Tadenan are not available.
INDICATIONS
- treatment of moderate functional disorders of the urinary system in benign prostatic hyperplasia (adenoma) (frequent urination during day and night, weak jet head, intermittent urination, feeling of incomplete emptying of the bladder, imperative urges and urination);
- condition after adenomectomy and prostatectomy.
DOSING MODE
The drug is administered orally 50 mg (1 capsule) 2 times / day in the morning and evening or 100 mg (2 capsules) 1 time / day, preferably before meals. The daily dose is 100 mg. The course of treatment on average is 6 weeks and can be increased to 8 weeks. If necessary, a repeat course of treatment is possible.
SIDE EFFECT
From the digestive system: rarely - constipation, nausea, decreased appetite, constipation, diarrhea.
On the part of the reproductive system: very rarely - gynecomastia, pain in testicles.
Allergic reactions: rarely - hives.
CONTRAINDICATIONS
- Hypersensitivity to the drug.
PREGNANCY AND LACTATION
The drug Tadenan is not intended for women.
SPECIAL INSTRUCTIONS
In benign prostatic hyperplasia, regular monitoring of the prostate gland condition, including periodic digital rectal examination to exclude prostate cancer, is necessary.
Therapy by Tadenan does not replace surgical intervention, if necessary.
Due to the fact that the preparation contains peanut butter, there is a risk of reactions of increased sensitivity.
OVERDOSE
Currently, data on the overdose of the drug Tadenan are absent.
DRUG INTERACTION
At present, there are no data on the drug interaction of the drug Tadenan.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 3 years.
